Notice of Interim Results

Oxford Biomedica PLC
02 August 2006


For Immediate Release                                              2 AUGUST 2006


                                        
                                OXFORD BIOMEDICA
                           NOTICE OF INTERIM RESULTS
                     FOR THE SIX MONTHS ENDED 30 JUNE 2006


Date: 5 September 2006


Oxford, UK - 2 August 2006: Oxford BioMedica (LSE: OXB), a leading gene therapy
company, announces that it will be releasing its interim results for the six
months ended 30 June 2006 on Tuesday, 5 September 2006.

Analyst meeting:

An analyst briefing will be held at 10:00 am on 5 September at the offices of
Buchanan Communications, 45 Moorfields, London EC2.

Web cast:

Simultaneously to the analyst briefing at 10.00 am, there will be a live audio
web cast of the results presentation.

To connect to the web cast facility, please go to the Company's website: 
http://www.oxfordbiomedica.co.uk/ approximately 10 minutes (09:50 am) before 
the start of the briefing. This will also be available for replay shortly after 
the presentation.


                                    -Ends-



For further information, please contact:
Oxford BioMedica plc:                                   Tel: [phone]
                                                                 
Professor Alan Kingsman, Chief Executive
City/Financial Enquiries:                               Tel: [phone]
                                                                       
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan
Communications
Scientific/Trade Press Enquiries:                       Tel: [phone]                              
Katja Stout/ Susan Yu/ Gemma Bradley

Northbank Communications


Notes to editors


1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on oncology and
neurotherapy. The Company was established in 1995 as a spin out from Oxford
University, and is listed on the London Stock Exchange.

Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes two candidates in multiple Phase II trials, and a preclinical targeted
antibody therapy in collaboration with Wyeth. A Phase III trial in renal cancer
with TroVax, the lead cancer immunotherapy candidate, is expected to start in
the second half of 2006. In neurotherapy, the Company's lead product is a gene
therapy for Parkinson's disease, which is expected to enter clinical development
in 2006, and four further preclinical candidates. The Company is underpinned by
over 80 patent families, which represent one of the broadest patent estates in
the field.

The Company has a staff of approximately 70 split between its main facilities in
Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.
Oxford BioMedica has corporate collaborations with Wyeth, Intervet,
Sigma-Aldrich, Viragen, MolMed, VIRxSYS and Kiadis; and has licensed technology
to a number of companies including Merck & Co, Biogen Idec and Pfizer.


Further information is available at www.oxfordbiomedica.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange